Axl Mediates ZIKA Virus Entry in Human Glial Cells and Modulates Innate Immune Responses
Laurent Meertens,
Athena Labeau,
Ophelie Dejarnac,
Sara Cipriani,
Laura Sinigaglia,
Lucie Bonnet-Madin,
Tifenn Le Charpentier,
Mohamed Lamine Hafirassou,
Alessia Zamborlini,
Van-Mai Cao-Lormeau,
Muriel Coulpier,
Dorothée Missé,
Nolwenn Jouvenet,
Ray Tabibiazar,
Pierre Gressens,
Olivier Schwartz,
Ali Amara
Affiliations
Laurent Meertens
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France; Corresponding author
Athena Labeau
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
Ophelie Dejarnac
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
Sara Cipriani
PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, 75019 Paris, France
Laura Sinigaglia
UMR CNRS 3569, Viral Genomics and Vaccination Unit, Pasteur Institute, 75724 Paris, France
Lucie Bonnet-Madin
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
Tifenn Le Charpentier
PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, 75019 Paris, France
Mohamed Lamine Hafirassou
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
Alessia Zamborlini
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France; Laboratoire PVM, Conservatoire des Arts et Metiers, 292 Rue Saint-Martin, 75003 Paris, France
Van-Mai Cao-Lormeau
Institut Louis Malardé, Papeete, Tahiti, French Polynesia
Muriel Coulpier
ANSES, Université Paris-Est, Ecole Nationale Vétérinaire d’Alfort, UMR Virologie, 94700 Maisons-Alfort, France
Dorothée Missé
Laboratoire MIVEGEC, UMR 224 IRD/CNRS, 34394 Montpellier, France
Nolwenn Jouvenet
UMR CNRS 3569, Viral Genomics and Vaccination Unit, Pasteur Institute, 75724 Paris, France
Ray Tabibiazar
Ruga Corporation, Two Houston Center, 909 Fannin St., #2000, Houston, TX 77010-1018, USA
Pierre Gressens
PROTECT, INSERM, Université Paris Diderot, Sorbonne Paris Cité, 75019 Paris, France
Olivier Schwartz
Unité Virus et Immunité, Institut Pasteur, 28 rue du Dr. Roux, 75724 Paris, France
Ali Amara
INSERM U944, CNRS 7212 Laboratoire de Pathologie et Virologie Moléculaire, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; Institut Universitaire d’Hématologie, Hôpital Saint-Louis, 1 avenue Claude Vellefaux, 75010 Paris, France; University Paris Diderot, Sorbonne Paris Cité, Hôpital St. Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France; Corresponding author
Summary: ZIKA virus (ZIKV) is an emerging pathogen responsible for neurological disorders and congenital microcephaly. However, the molecular basis for ZIKV neurotropism remains poorly understood. Here, we show that Axl is expressed in human microglia and astrocytes in the developing brain and that it mediates ZIKV infection of glial cells. Axl-mediated ZIKV entry requires the Axl ligand Gas6, which bridges ZIKV particles to glial cells. Following binding, ZIKV is internalized through clathrin-mediated endocytosis and traffics to Rab5+ endosomes to establish productive infection. During entry, the ZIKV/Gas6 complex activates Axl kinase activity, which downmodulates interferon signaling and facilitates infection. ZIKV infection of human glial cells is inhibited by MYD1, an engineered Axl decoy receptor, and by the Axl kinase inhibitor R428. Our results highlight the dual role of Axl during ZIKV infection of glial cells: promoting viral entry and modulating innate immune responses. Therefore, inhibiting Axl function may represent a potential target for future antiviral therapies. : ZIKA virus (ZIKV) is responsible for congenital microcephaly. Meertens et al. show that the Axl receptor is expressed in microglia and astrocytes in the human developing brain. They also highlight the dual role of Axl during infection, which promotes viral entry and dampens innate immune responses in glial cells.